ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer
Key Highlights
- ➤Farah Ali promoted to Chief Medical Officer, leading ProKidney’s clinical program.
- ➤PROACT 1 Phase 3 study of rilparencel advances toward potential commercialization.
- ➤Rilparencel targets advanced CKD and type 2 diabetes with potential kidney-function preservation.
- ➤Cash, equivalents and marketable securities expected to fund operations into mid-2027.
Expert Statements
Bruce Culleton, Chief Executive Officer of ProKidney
“Farah’s clinical background and drug development experience give her a unique perspective on the challenges patients face and the urgent need for new treatment options for individuals living with CKD.”
Bruce Culleton, Chief Executive Officer of ProKidney
“We are thrilled to recognize her contributions with this appointment and expanded leadership role as we work to advance a potential new treatment for patients living with advanced CKD and type 2 diabetes.”
Farah Ali, Chief Medical Officer of ProKidney
“ProKidney is pursuing a differentiated approach to addressing advanced CKD, with the potential to preserve kidney function and help patients delay the need for dialysis.”
Farah Ali, Chief Medical Officer of ProKidney
“I look forward to continuing to work alongside the team as we advance the PROACT 1 program, continue building the clinical and medical foundation for rilparencel, and prepare for the next stage of the Company’s growth.”
WINSTON-SALEM, N.C., Nov. 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the promotion of Farah Ali, M.D., M.S., to the role of Chief Medical Officer. Dr. Ali will lead the clinical program and team as ProKidney advances the pivotal Phase 3 PROACT 1 study of rilparencel and progresses toward potential commercialization.
“Farah’s clinical background and drug development experience give her a unique perspective on the challenges patients face and the urgent need for new treatment options for individuals living with CKD,” said Bruce Culleton, M.D., Chief Executive Officer of ProKidney. “We are thrilled to recognize her contributions with this appointment and expanded leadership role as we work to advance a potential new treatment for patients living with advanced CKD and type 2 diabetes.”
Get started
Create a free account to read the full story.
